4BB
NEUTRAL4basebio Appoints New Executive Chair
The biotechnology company has appointed a new Executive Chair, Dr. Manja Boerman, following an investment by Elevage Medical Technologies.
4basebio
995.50GBX
0.56%
Market Cap
154.15M
Volume
2.45k
356% of avg
P/E Ratio
-0.17
EPS (TTM)
-60
Beta
1.03
Day Range
980.00p - 1,000.00p
52 Week Range
940.00p995.50p1,550.00p
995.50p
4BB
NEUTRAL4basebio PLC Announces Major Shareholding Change
The biotechnology company has reported a change in major shareholding, with DELPHI Unternehmensberatung Aktiengesellschaft increasing its stake to over 33%.
4BB
NEUTRAL4basebio PLC Announces Director Dealings
The biotechnology company has announced changes to its major shareholders.
4BB
NEUTRAL4basebio PLC Announces Major Shareholder Holding Change
The biotechnology company has announced a change in the holdings of a major shareholder.
4BB
NEUTRAL4basebio PLC Announces Change in Shareholding
The biotechnology company has announced a change in its major shareholding structure.
4BB
NEUTRAL4basebio Announces Exercise of Employee Share Options
The biotechnology company has announced that two employees have exercised EMI options over 13,000 ordinary shares, raising total proceeds of £15,340.
4BB
NEUTRAL4basebio PLC Announces Director Dealings
The biotechnology company has announced a change in major shareholdings.
4BB
NEUTRAL4basebio PLC Announces Major Shareholder Disclosure
The biotechnology company has received a notification of a change in major shareholder holdings.
4BB
NEUTRAL4basebio PLC Reports Doubled DNA Revenues but Widening Losses in 2024 Results
The biotechnology firm doubled its DNA revenues but reported widening losses. Despite securing significant funding and expanding its customer base, the company expects to remain loss-making in 2025.
4BB
NEUTRAL4basebio CEO Increases Stake
The CEO of the biotechnology company has purchased additional shares in the business on behalf of his children.